A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

Completed · Phase 3

Conditions studied: Migraine

In brief

This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity. Qualified subjects will receive study medication for up to twelve months for the treatment of multiple migraine attacks. Using the electronic diary (eDiary) to confirm they are experiencing a qualified migraine, subjects will self-administer the patches and respond to questions in the eDiary post treatment administration.

Key facts

Study ID
NCT03282227
Run by
Zosano Pharma Corporation
People needed
342
Starts
2017-11-07
Expected to finish
2019-05-17
Last updated by the study team
2020-08-19

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.